Drug Trial Radar · NCT03985943
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Aug 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
941
Actual
Start
Jun 27, 2019
Primary completion
Dec 29, 2021
Study completion Aug 11, 2022
Sponsor
- Lead sponsor
- Galderma R&DIndustry
- Sponsor type
- Industry
- First posted
- Jun 14, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of the study was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments.
Conditions
- Moderate-to-Severe Atopic Dermatitis
Interventions
PlaceboDrug
Placebo
NemolizumabDrug
Nemolizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT) PopulationTime frame: Week 16
- Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a >= 2-point Reduction): Severe Pruritus PopulationTime frame: Week 16
- Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at Week 16: ITT PopulationTime frame: Week 16
- Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at 16: Severe Pruritus PopulationTime frame: Week 16
Locations
174 sites in 14 countries. Site status is shown where the registry gives one.
Galderma Investigational Site 8880
North Little Rock, Arkansas
Galderma Investigational Site 8578
Cerritos, California
Galderma Investigational Site 8636
Fountain Valley, California
Galderma Investigational Site 8888
Fullerton, California
Galderma Investigational Site 8686
Lomita, California
Galderma Investigational Site 8674
Los Angeles, California
Galderma Investigational Site 8125
San Francisco, California
Galderma Investigational Site 8895
Santa Ana, California
Galderma Investigational Site 8608
Santa Monica, California
Galderma Investigational Site 8897
Brandon, Florida
Galderma Investigational Site 8805
Cape Coral, Florida
Galderma Investigational Site 8902
Doral, Florida
Galderma Investigational Site 8804
Hialeah, Florida
Galderma Investigational Site 8711
Jacksonville, Florida
Galderma Investigational Site 8710
Miami, Florida
Galderma Investigational Site 8801
Miami, Florida
Galderma Investigational Site 8737
Miami, Florida
Galderma Investigational Site 8708
Miami, Florida
Galderma Investigational Site 8806
Miami Lakes, Florida
Galderma Investigational Site 8800
Miami Lakes, Florida
Galderma Investigational Site 8734
Pembroke Pines, Florida
Galderma Investigational Site 8744
Macon, Georgia
Galderma Investigational Site 8728
Newnan, Georgia
Galderma Investigational Site 8887
Union City, Georgia
Galderma Investigational Site 8890
Blackfoot, Idaho
Galderma Investigational Site 8819
Nampa, Idaho
Galderma Investigational Site 8571
Skokie, Illinois
Galderma Investigational Site 8712
Skokie, Illinois
Galderma Investigational Site 8142
Indianapolis, Indiana
Galderma Investigational Site 8771
Louisville, Kentucky
Galderma Investigational Site 8882
Bangor, Maine
Galderma Investigational Site 8743
Ann Arbor, Michigan
Galderma Investigational Site 8512
Bay City, Michigan
Galderma Investigational Site 8155
Troy, Michigan
Galderma Investigational Site 8748
Ypsilanti, Michigan
Galderma Investigational Site 8521
Saint Joseph, Missouri
Galderma Investigational Site 8718
Missoula, Montana
Galderma Investigational Site 8810
Omaha, Nebraska
Galderma Investigational Site 8740
Henderson, Nevada
Galderma Investigational Site 8242
Brooklyn, New York
Showing 40 of 174 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.